BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19767197)

  • 1. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry.
    Gigliotti AR; Di Cataldo A; Sorrentino S; Parodi S; Rizzo A; Buffa P; Granata C; Sementa AR; Fagnani AM; Provenzi M; Prete A; D'Ippolito C; Clerico A; Castellano A; Tonini GP; Conte M; Garaventa A; De Bernardi B
    Eur J Cancer; 2009 Dec; 45(18):3220-7. PubMed ID: 19767197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma.
    Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
    Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
    Rubie H; Plantaz D; Coze C; Michon J; Frappaz D; Baranzelli MC; Chastagner P; Peyroulet MC; Hartmann O;
    Med Pediatr Oncol; 2001 Jan; 36(1):247-50. PubMed ID: 11464897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry.
    Haupt R; Garaventa A; Gambini C; Parodi S; Cangemi G; Casale F; Viscardi E; Bianchi M; Prete A; Jenkner A; Luksch R; Di Cataldo A; Favre C; D'Angelo P; Zanazzo GA; Arcamone G; Izzi GC; Gigliotti AR; Pastore G; De Bernardi B
    J Clin Oncol; 2010 May; 28(14):2331-8. PubMed ID: 20351331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
    De Bernardi B; Nicolas B; Boni L; Indolfi P; Carli M; Cordero Di Montezemolo L; Donfrancesco A; Pession A; Provenzi M; di Cataldo A; Rizzo A; Tonini GP; Dallorso S; Conte M; Gambini C; Garaventa A; Bonetti F; Zanazzo A; D'Angelo P; Bruzzi P;
    J Clin Oncol; 2003 Apr; 21(8):1592-601. PubMed ID: 12697885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.
    Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J
    J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
    Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
    Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
    Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
    Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol.
    Olgun N; Kansoy S; Aksoylar S; Cetingul N; Vergin C; Oniz H; Sarialioglu F; Kantar M; Uysal K; Tuncyurek M; Kargi A; Aktas S; Bayol U; Karaca I; Arikan A; Balik E; Aktug T; Elmas N; Kovanlikaya A; Kinay M; Anacak Y; Degirmenci B; Burak Z
    Pediatr Hematol Oncol; 2003; 20(3):211-8. PubMed ID: 12637217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
    Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M
    J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management strategy in neuroblastoma].
    Balwierz W
    Przegl Lek; 2004; 61 Suppl 2():3-8. PubMed ID: 15686038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
    Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
    Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.
    De Bernardi B; Gerrard M; Boni L; Rubie H; Cañete A; Di Cataldo A; Castel V; Forjaz de Lacerda A; Ladenstein R; Ruud E; Brichard B; Couturier J; Ellershaw C; Munzer C; Bruzzi P; Michon J; Pearson AD
    J Clin Oncol; 2009 Mar; 27(7):1034-40. PubMed ID: 19171711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies.
    van Noesel MM; Hählen K; Hakvoort-Cammel FG; Egeler RM
    Cancer; 1997 Sep; 80(5):834-43. PubMed ID: 9307181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
    Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
    Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
    Zacharoulis S; Levy A; Chi SN; Gardner S; Rosenblum M; Miller DC; Dunkel I; Diez B; Sposto R; Ji L; Asgharzadeh S; Hukin J; Belasco J; Dubowy R; Kellie S; Termuhlen A; Finlay J
    Pediatr Blood Cancer; 2007 Jul; 49(1):34-40. PubMed ID: 16874765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.